Search for:
Search for:
Healthcare Professionals
Publications
News
EspaƱol
Contact
Magazine
Radio
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
MS Focus At Sea
MS Focus At Sea offers educational programs, opportunities to meet old and new friends, and adventures for every...
/Events/MSF-Events/MSFocus-Cruise-For-A-Cause
Healthcare Assistance ...
The MS Focus Healthcare Assistance Grant assists uninsured individuals with the cost of visiting...
/Get-Help/MSF-Programs-Grants/Healthcare-Assistance-Grant
Shop
Privacy
Terms of Use
Site Map
Researchers ID possible MS biomarker
October 16, 2017
A new study identifies opioid growth factor (OGF) as a possible biomarker for the onset and progression of multiple sclerosis. The study found OGF levels were lower in patients with MS when compared to non-MS patients and MS-patients receiving disease-modifying therapies.
In the current study, researchers at Penn State University College of Medicine in Hershey, Penn., looked at OGF levels in MS patients as well as an MS animal model. Serum levels of OGF were significantly reduced in MS patients when compared to normal individuals. Collaborative studies in the mouse model of MS found that reductions in OGF were predictive of disease development. Low dose naltrexone treatment restored OGF levels in EAE mice and had no effect on OGF levels in normal mice.
Low dose naltrexone is an off-label therapeutic prescribed for a variety of immune-related disorders, including MS. Naltrexone intermittently blocks the opioid receptors that control pain, reward, and addictive behavior, resulting in biofeedback events that increase production of OGF. Although LDN positively affects the quality-of-life and fatigue levels in MS patients, its mechanism of action in MS patients has not been confirmed.
The results of mouse model studies sometimes do not translate to humans and may be years away from being a marketable treatment. However, the authors said these findings, along with the availability of noninvasive technology for measuring OGF levels in patients, support OGF as a candidate biomarker for MS.
The article was published in
Experimental Biology and Medicine
.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more